Efficiency of Spatially Distributed Sequential Stimulation (Sdss) for Functional Electrical Stimulation (FES) of Upper Motor Neuron Syndrome (UMR) Patients
Launched by UGECAM RHÔNE-ALPES · May 17, 2024
Trial Information
Current as of February 08, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new method called Spatially Distributed Sequential Stimulation (Sdss) to see if it is more effective than the standard electrical stimulation used for patients with Upper Motor Neuron Syndrome (UMR). UMR patients often experience weakness in their muscles due to conditions affecting the brain and spinal cord. The goal of the trial is to find out if this new stimulation method can better help improve muscle function and movement for these patients.
To participate in this trial, individuals need to be adults over 18 years old who have muscle weakness from an injury or disease affecting their nervous system. They should be in a stable health condition, especially regarding their heart, and should be able to tolerate electrical stimulation without any issues. Participants will be expected to complete cycling exercises for about 30 minutes using the stimulation method being tested. It's important to note that those with certain heart conditions, severe cognitive issues, or who are currently pregnant cannot join the study. If eligible, participants will have a chance to contribute to important research that could improve treatments for muscle weakness in UMR patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients with Upper Motor Neuron syndrome:
- • adult (\> 18 years)
- • motor deficit due to an acquired traumatic or neurodegenerative motor deficiency of the central nervous system (MRC\<4/5)
- • stable clinical condition, particularly on the cardiovascular level (recent assessment by a cardiologist with stress test)
- • non denervated muscles
- • tolerant to muscle electrical stimulation
- • having given written consent
- • able to cycle 30 minutes with FES-cycling
- Exclusion Criteria:
- • major cognitive comprehension disorders that could compromise understanding of the protocol and the smooth running of the study
- • cardiac pacemaker and other contraindications relating to the use of electrostimulation (in particularly "deep vein thrombosis")
- • spasticity of the lower limbs making flexion/extension movement difficult
- • participation in another study
- • pregnancy
- * people with the following legal and administrative states or situations:
- • people placed under judicial protection;
- • persons deprived of their liberty, persons subject to psychiatric care and persons admitted to a health or social establishment for purposes other than that of clinical investigation;
- • unemancipated minors;
- • people who are not affiliated to a social security scheme or beneficiaries of such a scheme
About Ugecam Rhône Alpes
Ugecam Rhône-Alpes is a prominent clinical trial sponsor dedicated to advancing healthcare through innovative research and development in the field of rehabilitation and disability care. Operating within the Ugecam network, which is known for its commitment to quality and patient-centered approaches, Ugecam Rhône-Alpes collaborates with healthcare professionals and research institutions to conduct rigorous clinical trials that aim to improve therapeutic outcomes and enhance the quality of life for patients. Their focus on evidence-based practices and adherence to ethical standards ensures that their studies contribute valuable insights to medical science and foster advancements in healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Didier Au Mont D'or, , France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0